Adynotyline Nears Phase IV

Associated Press
October 3, 2010

When you mention the drug Adynotyline, most people on the street likely aren't aware of what you're speaking of. Initially entering the FDA approval process in the summer of 2007, Adynotyline represents a long and laborious process of the United States Government's plan to cope with the changes in the world put forth by the revelation of the Suresh Linkage Complex and individuals that express SLC-based extraordinary abilities.

Adynotyline, when it reaches Phase IV of FDA testing, will mark the appearance of a short-term chemical suppressant for any individual bearing an SLC-expressive ability, and it will be available to the public.

If you're wondering why you hadn't heard about this proposed miracle drug before, there's good reason. Developed by the Commonwealth Institute of Massachusetts, Adynotyline had been listed in the FDA as an antidepressant and anti-psychotic due to the chemical composition and the lack of a formal categorization for SLC-targeted drugs. It was only within the last week that results from the latest round of FDA testing were made public, revealing the candidate list for volunteers of Adynotyline testing were all Registered Evolved.

Currently 3,000 Americans are involved in the testing phase of Adynotyline, and it is expected that the drug will reach Phase IV by March of next year where it will become available by prescription from a licensed physician.

The revelation of Adynotyline's intended use to the public has raised eyebrows on both sides of the Registration fence. Opponents of the Linderman Act have openly raised fears that the drug may become required of some registrants, especially those with potentially dangerous or hazardous abilities. However proponents of the act note that the presence of SLC-expressive ability testing and Adynotyline will be a cornerstone in helping individuals who cannot control their abilities from unintentionally bringing harm to others, and preventing another Midtown tragedy.

Doctor Jean Martin Luis of the Commonwealth Institute, one of the minds behind Adynotyline's development, has stated "I have hope that with the release of Adynotyline to the public it will be the first step that this country can take to truly feeling secure. My first and foremost concern is for the safety and protection of the SLC-expressive in this country and I have devoted my life to research that will further this end."

Luis went on to say, "Adynotyline is just one step in a long process of society's game of 'catch up' to the way the world truly is. We had been blind to the presence of the Evolved for so long that science and medicine advanced without taking their needs and concerns into consideration."

Doctor Jean Martin Luis is scheduled to hold a town-hall style lecture on the Evolved at the Chandra Suresh Memorial Center on October 5th, Adynotyline will likely be a topic of discussion.

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License